Literature DB >> 34872726

BRAF Inhibitors in Melanoma Management: When Friends Become Foes.

Gagan Chhabra1, Nihal Ahmad2.   

Abstract

The BRAF inhibitor (BRAFi) vemurafenib improves survival of patients with melanoma with BRAFV600E mutations. However, effects of sustained BRAFis on BRAFi-resistant melanomas with dual mutations in BRAF and NRAS are not well characterized. Jandova and Wondrak (2021) report that vemurafenib selectively enhances expression of genes involved in the epithelial-to-mesenchymal transition in BRAFV600E/NRASQ61K melanoma cells, paradoxically promoting tumor growth and metastasis in mice. This preclinical study provides compelling reasons to be cautious in the use of BRAFis in patients with NRAS-driven melanoma.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34872726      PMCID： PMC9199497          DOI： 10.1016/j.jid.2021.11.005

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   7.590


  10 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.

Authors:  Chengqian Yin; Bo Zhu; Ting Zhang; Tongzheng Liu; Shuyang Chen; Yu Liu; Xin Li; Xiao Miao; Shanshan Li; Xia Mi; Jie Zhang; Li Li; Guo Wei; Zhi-Xiang Xu; Xiumei Gao; Canhua Huang; Zhi Wei; Colin R Goding; Peng Wang; Xianming Deng; Rutao Cui
Journal:  Cell       Date:  2019-01-31       Impact factor: 41.582

Review 3.  Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.

Authors:  Ross L Pearlman; Mary Katherine Montes de Oca; Harish Chandra Pal; Farrukh Afaq
Journal:  Cancer Lett       Date:  2017-01-25       Impact factor: 8.679

4.  COMBATING NRAS MUTANT MELANOMA: FROM BENCH TO BEDSIDE.

Authors:  Ileabett M Echevarría-Vargas; Jessie Villanueva
Journal:  Melanoma Manag       Date:  2017-11-21

5.  Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAFV600E/NRASQ61K Melanoma Enhancing Tumor Growth and Metastasis in a Bioluminescent Murine Model.

Authors:  Jana Jandova; Georg T Wondrak
Journal:  J Invest Dermatol       Date:  2021-10-21       Impact factor: 7.590

6.  Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.

Authors:  Malihe Eskandarpour; Fei Huang; Karen A Reeves; Edwin Clark; Johan Hansson
Journal:  Int J Cancer       Date:  2009-01-01       Impact factor: 7.396

7.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms.

Authors:  Douglas B Johnson; Alexander M Menzies; Lisa Zimmer; Zeynep Eroglu; Fei Ye; Shilin Zhao; Helen Rizos; Antje Sucker; Richard A Scolyer; Ralf Gutzmer; Helen Gogas; Richard F Kefford; John F Thompson; Jürgen C Becker; Carola Berking; Friederike Egberts; Carmen Loquai; Simone M Goldinger; Gulietta M Pupo; Willy Hugo; Xiangju Kong; Levi A Garraway; Jeffrey A Sosman; Antoni Ribas; Roger S Lo; Georgina V Long; Dirk Schadendorf
Journal:  Eur J Cancer       Date:  2015-11-19       Impact factor: 9.162

8.  Efficient Suppression of NRAS-Driven Melanoma by Co-Inhibition of ERK1/2 and ERK5 MAPK Pathways.

Authors:  Christian Adam; Lorenza Fusi; Neele Weiss; Simon G Goller; Katharina Meder; Verena G Frings; Hermann Kneitz; Matthias Goebeler; Roland Houben; David Schrama; Marc Schmidt
Journal:  J Invest Dermatol       Date:  2020-05-04       Impact factor: 8.551

Review 9.  Epithelial-to-mesenchymal-like transition events in melanoma.

Authors:  Dennis Pedri; Panagiotis Karras; Ewout Landeloos; Jean-Christophe Marine; Florian Rambow
Journal:  FEBS J       Date:  2021-05-30       Impact factor: 5.542

10.  MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAFV600E Mutation Detected in Circulating-Free DNA.

Authors:  Rossella Salemi; Luca Falzone; Gabriele Madonna; Jerry Polesel; Diana Cinà; Domenico Mallardo; Paolo A Ascierto; Massimo Libra; Saverio Candido
Journal:  Front Pharmacol       Date:  2018-08-14       Impact factor: 5.810
  10 in total
  1 in total

1.  Mefloquine induces ER stress and apoptosis in BRAFi-resistant A375-BRAFV600E /NRASQ61K malignant melanoma cells targeting intracranial tumors in a bioluminescent murine model.

Authors:  Jana Jandova; Sophia L Park; Mandi J Corenblum; Lalitha Madhavan; Jeremy A Snell; Liliana Rounds; Georg T Wondrak
Journal:  Mol Carcinog       Date:  2022-04-13       Impact factor: 5.139
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.